Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer

Por Hyman, David M., Spriggs, David R.
Publicado em 2012

Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents

Por Rao, Thapi D., Rosales, Nestor, Spriggs, David R.
Publicado em 2011

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma

Por Yeku, Oladapo, Russo, Andrea L., Lee, Hang, Spriggs, David
Publicado no J Transl Med (2020)

Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study

Por Mould, Diane R, Fleming, Gini F, Darcy, Kathleen M, Spriggs, David
Publicado em 2006

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo

Por Koneru, Mythili, Purdon, Terence J., Spriggs, David, Koneru, Susmith, Brentjens, Renier J.
Publicado no Oncoimmunology (2015)

A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies

Por Iasonos, Alexia, Wilton, Andrew S, Riedel, Elyn R, Seshan, Venkatraman E, Spriggs, David R
Publicado em 2008

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer

Por Koneru, Mythili, O’Cearbhaill, Roisin, Pendharkar, Swati, Spriggs, David R, Brentjens, Renier J
Publicado no J Transl Med (2015)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

Por Yeku, Oladapo O., Purdon, Terence J., Koneru, Mythili, Spriggs, David, Brentjens, Renier J.
Publicado no Sci Rep (2017)

Galectins and Ovarian Cancer

Por Shimada, Chisa, Xu, Rui, Al-Alem, Linah, Stasenko, Marina, Spriggs, David R., Rueda, Bo R.
Publicado no Cancers (Basel) (2020)

The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells

Por Bellio, Chiara, DiGloria, Celeste, Spriggs, David R., Foster, Rosemary, Growdon, Whitfield B., Rueda, Bo R.
Publicado no Cancers (Basel) (2019)

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials

Por Iasonos, Alexia, Gounder, Mrinal, Spriggs, David R, Gerecitano, John F, Hyman, David M, Zohar, Sarah, O’Quigley, John
Publicado em 2012

Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers

Por Hyman, David M., Zhou, Qin, Arnold, Angela G., Grisham, Rachel N., Iasonos, Alexia, Kauff, Noah D., Spriggs, David
Publicado em 2011

Time to publication of oncology trials and why some trials are never published

Por Chapman, Paul B., Liu, Nathan J., Zhou, Qin, Iasonos, Alexia, Hanley, Sara, Bosl, George J., Spriggs, David R.
Publicado no PLoS One (2017)

Identifying Clinical Improvement in Consolidation Single-arm Phase II Trials in Ovarian Cancer Patients in Second or Greater Clinical Remission

Por Iasonos, Alexia, Sabbatini, Paul, Spriggs, David R., Aghajanian, Carol A., O’Cearbhaill, Roisin E., Hensley, Martee L., Thaler, Howard T.
Publicado em 2012

Novel Monoclonal Antibodies against the Proximal (Carboxy-Terminal) Portions of MUC16

Por Rao, Thapi Dharma, Park, Kay J., Smith-Jones, Peter, Iasonos, Alexia, Linkov, Irina, Soslow, Robert A., Spriggs, David R.
Publicado no Appl Immunohistochem Mol Morphol (2010)

Duration of Second or Greater Complete Clinical Remission In Ovarian Cancer: Exploring Potential Endpoints for Clinical Trials

Por Harrison, Michelle L, Gore, Martin E, Spriggs, David, Kaye, Stan, Iasonos, Alexia, Hensley, Martee, Aghajanian, Carol, Venkatraman, Ennapadam, Sabbatini, Paul
Publicado em 2007

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen

Por Chekmasova, Alena A., Rao, Thapi D., Nikhamin, Yan, Park, Kay J., Levine, Douglas A., Spriggs, David R., Brentjens, Renier J.
Publicado em 2010

Consolidation Strategies in Ovarian Cancer: Observations for Future Clinical Trials

Por Sabbatini, Paul, Spriggs, David, Aghajanian, Carol, Hensley, Martee, Tew, William, Konner, Jason, Bell-McGuinn, Kathryn, Juretzka, Margrit, Iasonos, Alexia
Publicado em 2010

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Por Seymour, Lesley, Groshen, Susan, Rosner, Gary L., Sullivan, Daniel M., Spriggs, David R., Reeves, Steven, Gravell, Amy, Ivy, S. Percy, Ratain, Mark J.
Publicado no Clin Cancer Res (2015)

CA-125 Change Following Chemotherapy in Prediction of Treatment Outcome among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers: A Gynecologic Oncology Group Study

Por Tian, Chunqiao, Markman, Maurie, Zaino, Richard, Ozols, Robert F., McGuire, William P., Muggia, Franco M., Rose, Peter G., Spriggs, David, Armstrong, Deborah K.
Publicado em 2009